Latest Administration News

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.

Immutep Limited reports strong progress in its Phase III lung cancer trial with over 170 patients enrolled, alongside positive FDA feedback and a robust cash position supporting ongoing development.

Novo Resources reported a narrowed Q3 2025 net loss amid active exploration in Western Australia and New South Wales, boosted by a significant share sale that enhanced liquidity.

Novo Resources Corp. reported a reduced net loss of CAD 9.7 million for the nine months to September 2025, supported by lower operating cash outflows and a significant post-period sale of San Cristobel Mining shares. The company maintains a cautious outlook amid ongoing funding needs.

Triangle Energy (Global) Limited has amended its quarterly cash flow report to correct key figures while advancing new permits in the Philippines and progressing the transition of its Cliff Head Oil Field to a carbon capture and storage project.

Jatcorp’s Q1 FY26 revenue dipped 8% following a record Q4, yet the company advanced key growth initiatives including Southeast Asia expansion and a leadership change.

Freehill Mining Limited has addressed an ASX query over the late filing of a director’s interest notice, attributing the delay to an administrative oversight and reaffirming its compliance protocols.

Radiopharm Theranostics has secured FDA approval to initiate a Phase I trial targeting B7H3 and raised A$40 million to accelerate its radiopharmaceutical programs. The company also appointed renowned oncologist Dr Oliver Sartor to its Scientific Advisory Board.

Energy World Corporation focused on advancing its capital raising and asset sales in Q3 2025, ending the quarter with $15 million in cash but no revenue generation.

Cycliq Group has completed a major e-commerce platform upgrade while preparing inventory for the critical Cyber November sales, reporting a 35% drop in quarterly customer receipts as it invests in future growth.

Anteris Technologies Global Corp. has raised A$38.5 million in a private placement to accelerate the global commercialization and pivotal clinical trial of its innovative DurAVR® transcatheter aortic valve replacement device.

Neurotech International has initiated an Authorised Prescriber program for its lead therapy NTI164, expanding access for children with neurodevelopmental disorders in Australia. The company also secured a Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett Syndrome, marking a key regulatory milestone.